Clinical implementation of KRAS testing in metastatic colorectal carcinoma the pathologist's perspective

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 10, 2012, Pages 1298-1307

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CARCINOMA; COLORECTAL TUMOR; GENETIC SCREENING; GENETICS; HUMAN; METHODOLOGY; NUCLEOTIDE SEQUENCE; ONCOLOGY; PATHOLOGY; PHYSICIAN; PRACTICE GUIDELINE; REVIEW; STANDARD;

CARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENETIC TESTING; HUMANS; MEDICAL ONCOLOGY; PATHOLOGY; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84868329014     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0478-RA     Document Type: Review

References (58)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
2. Van Cutsem E, Bajetta E, Valle J, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011-2019.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17): 1757-1765.
4. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28(31):4697-4705.
5. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706-4713.
6. Erbitux [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2011. 7. Vectibix.
7. [package insert]. Thousand Oaks, CA: Amgen Inc; 2011.
8. College of American Pathologists. POET Report: perspectives on emerging technology: KRAS testing for colorectal cancer. http://www.cap.org/apps/docs/ committees/technology/KRAS.pdf. Published September 2009. Accessed November 22, 2011.
9. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD: Lippincott, Williams & Wilkins; 1996.
10. Lièvre A, Bachet J, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379.
11. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508-515.
12. Khambata-Ford S, Garrett C, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22): 3230-3237.
13. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007;96(8):1166-1169.
14. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643-2648.
15. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14): 1408-1417.
16. Punt C, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) [abstract]. J Clin Oncol. 2008;26(15 suppl): LBA4011.
17. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671.
18. Allegra C, Jessup M, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti- epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096.
19. Ciardiello F, Tejpar S, Normanno N, et al. 2011. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol. 2011;6(3):133-145.
20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer V2.2012. http://www.nccn.org/professionals/physician- gls/pdf/colon.pdf. Accessed November 22, 2011.
21. van Krieken J, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453(5):417-431.
22. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008;26(25):4217-4219.
23. Kotoula V, Charalambous E, Biesmans B, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009;4(11):e7746.
24. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol. 2010;5:23.
25. Herreros-Villanueva M, Aggarwal G. KRAS assay selection: sensitivity and accuracy in clinical application [published online ahead of print June 9, 2011].
26. Soulieres D, Greer W, Magliocco AM, et al. 2010. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol. 2010;17(suppl 1):S31-S40.
27. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11(6):543-552.
28. Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res. 2011;17(14):4901- 4914.
29. Ross J, Lipson R, Yelensky R, et al. Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues [abstract]. J Clin Oncol. 2011;29(15 suppl):10564.
30. Sorenson GD. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res. 2000; 6(6):2129-2137.
31. Chien CC, Chen SH, Liu CC, et al. Correlation of K-RAS codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC). Transl Res. 2007;149(2):96-102.
32. Haug U, Hillebrand T, Bendzko P, et al. Mutant-enriched PCR and allelespecific hybridization reaction to detect K-ras mutations in stool DNA: high prevalence in a large sample of older adults. Clin Chem. 2007;53(4):787-790.
33. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93(11): 858-865.
34. Pallisgaard N, Spindler K, Vogelius IS, and Jakobsen AKM. Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan [abstract]. J Clin Oncol. 2011;29(15 suppl):3599.
35. Punnoose E, Atwal S, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010;5(9):e12517.
36. Bellon E, Ligtenberg M, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist. 2011;16(4):467-478.
37. Hewitt SM, Lewis FA, Cao Y. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132(12): 1929-1935.
38. US Department of Health and Human Services. Centers for Medicare and Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA). http://www.cms.gov/clia. Accessed November 22, 2011.
39. College of American Pathologists. Accreditation and laboratory improvement. http://www.cap.org/apps/cap.portal?-nfpb5true&- pageLabel5accreditation. Accessed August 31, 2011.
40. Gulley M, Braziel R, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131(6):852-863.
41. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304(16): 1812-1820.
42. Tejpar S, Bokemeyer C, Celik I, et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab [abstract]. J Clin Oncol. 2011; 29(15 suppl):3511.
43. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146, and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101(4):715-721.
44. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer V2.2011. http://www.nccn.org/professionals/physician- gls/pdf/breast.pdf. Accessed November 22, 2011.
45. Bardelli A, Siena A. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254-1261.
46. Laurent-Puig P, Cayre, A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924-5930.
47. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multideterminants analysis of molecular alterations for predicting clinical benefit to EGFR targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009; 4(10):e7287.
48. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-762.
49. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-5712.
50. Khambata-Ford S, Harbison C, Hart L, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(6):918-927.
51. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011;12(8):795-805.
52. Linardou H, Dahabreh IJ, Kanaloupiti D, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962-972.
53. Zhu C, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26(26):4268-4275.
54. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(31):4113-4120.
55. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28(5): 744-752.
56. Chapman P, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
57. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol. 2010;28(15 suppl): 3534.
58. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535- 1546.